198 related articles for article (PubMed ID: 35603131)
21. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India.
Dravid A; Betha TP; Sharma AK; Gawali R; Mahajan U; Kulkarni M; Saraf C; Kore S; Dravid M; Rathod N
HIV Med; 2020 Oct; 21(9):578-587. PubMed ID: 33021066
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
DeJesus E; Saleh S; Cheng S; van der Mey D; Becker C; Frey R; Unger S; Mueck W
Pulm Circ; 2019; 9(2):2045894019848644. PubMed ID: 30997864
[TBL] [Abstract][Full Text] [Related]
24. AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial.
Zhao Y; Keene C; Griesel R; Sayed K; Gcwabe Z; Jackson A; Ngwenya O; Schutz C; Goliath R; Cassidy T; Goemaere E; Hill A; Maartens G; Meintjes G
Wellcome Open Res; 2021; 6():33. PubMed ID: 36017341
[No Abstract] [Full Text] [Related]
25. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.
Bansi-Matharu L; Phillips A; Oprea C; Grabmeier-Pfistershammer K; Günthard HF; De Wit S; Guaraldi G; Vehreschild JJ; Wit F; Law M; Wasmuth JC; Chkhartishvili N; d'Arminio Monforte A; Fontas E; Vesterbacka J; Miro JM; Castagna A; Stephan C; Llibre JM; Neesgaard B; Greenberg L; Smith C; Kirk O; Duvivier C; Dragovic G; Lundgren J; Dedes N; Knudsen A; Gallant J; Vannappagari V; Peters L; Elbirt D; Sarcletti M; Braun DL; Necsoi C; Mussini C; Muccini C; Bolokadze N; Hoy J; Mocroft A; Ryom L
Lancet HIV; 2021 Nov; 8(11):e711-e722. PubMed ID: 34555326
[TBL] [Abstract][Full Text] [Related]
26. Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries.
Romo ML; Esber AL; Owuoth J; Maswai J; Sing'oei V; Iroezindu M; Bahemana E; Kibuuka H; Cavanaugh JS; Shah N; Ake JA; Crowell TA;
HIV Med; 2023 Oct; 24(10):1066-1074. PubMed ID: 37232057
[TBL] [Abstract][Full Text] [Related]
27. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
28. Comparison of cumulative viraemia following treatment initiation with different antiretroviral regimens: a real-life study in Brazil.
Pascom AR; Pinho RE; Rick F; Veras NM; Perini FB; Meireles MV; Pereira GF; Benzaken AS; Avelino-Silva VI
J Int AIDS Soc; 2019 Nov; 22(11):e25397. PubMed ID: 31743620
[TBL] [Abstract][Full Text] [Related]
29. The First Experience of Effective 3rd Line Antiretroviral Therapy - A Case of 40-Year-Old Female Retroviral-Infected Patient at Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia.
Ketema W; Taye K; Shibeshi MS; Tagesse N; Hirigo AT; Woubishet K; Gutema S; Eifa A; Toma A
Res Rep Trop Med; 2021; 12():263-266. PubMed ID: 34858075
[TBL] [Abstract][Full Text] [Related]
30. The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review.
Aprilianti S; Utami AM; Suwantika AA; Zakiyah N; Azis VI
Clinicoecon Outcomes Res; 2024; 16():25-34. PubMed ID: 38293254
[TBL] [Abstract][Full Text] [Related]
31. Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.
Asare K; Lewis L; van der Molen J; Sookrajh Y; Khubone T; Moodley P; Lessells RJ; Naidoo K; Sosibo P; Garrett N; Dorward J
Open Forum Infect Dis; 2023 Dec; 10(12):ofad583. PubMed ID: 38045558
[TBL] [Abstract][Full Text] [Related]
32. Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
De Wit S; Bonnet F; Osiyemi O; Bisshop F; Olalla J; Routy JP; Wyen C; Moodley R; Pappa K; Wang R; Oyee J; Saggu P; Letang E; Wynne B; Jones B; Smith KY; Ait-Khaled M
J Acquir Immune Defic Syndr; 2024 Mar; ():. PubMed ID: 38346427
[TBL] [Abstract][Full Text] [Related]
33. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
Radford M; Parks DC; Ferrante S; Punekar Y
AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
[TBL] [Abstract][Full Text] [Related]
35. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
[TBL] [Abstract][Full Text] [Related]
36. Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
Kouamou V; Washaya T; Ndhlovu CE; Manasa J
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766288
[TBL] [Abstract][Full Text] [Related]
37. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis.
Kanters S; Vitoria M; Zoratti M; Doherty M; Penazzato M; Rangaraj A; Ford N; Thorlund K; Anis PAH; Karim ME; Mofenson L; Zash R; Calmy A; Kredo T; Bansback N
EClinicalMedicine; 2020 Nov; 28():100573. PubMed ID: 33294805
[TBL] [Abstract][Full Text] [Related]
39. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.
Vasylyev M; Wit FWNM; Jordans CCE; Soetekouw R; van Lelyveld SFL; Kootstra GJ; Delsing CE; Ammerlaan HSM; van Kasteren MEE; Brouwer AE; Leyten EMS; Claassen MAA; Hassing RJ; den Hollander JG; van den Berge M; Roukens AHE; Bierman WFW; Groeneveld PHP; Lowe SH; van Welzen BJ; Richel O; Nellen JF; van den Berk GEL; van der Valk M; Rijnders BJA; Rokx C
Open Forum Infect Dis; 2024 Apr; 11(4):ofae160. PubMed ID: 38567196
[TBL] [Abstract][Full Text] [Related]
40. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
